Generic Inveltys Availability
Last updated on Sep 11, 2024.
Inveltys is a brand name of loteprednol ophthalmic, approved by the FDA in the following formulation(s):
INVELTYS (loteprednol etabonate - suspension/drops;ophthalmic)
-
Manufacturer: ALCON LABS INC
Approval date: August 22, 2018
Strength(s): 1% [RLD]
Has a generic version of Inveltys been approved?
No. There is currently no therapeutically equivalent version of Inveltys available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Inveltys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent 10,058,511
Issued: August 28, 2018
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Bourassa James & Gardner Colin R. & Chen Hongming & Ensign Laura M. & Lai Samuel K. & Yu Tao & Hanes Justin & Yang Ming
Assignee(s): The Johns Hopkins UniversityNanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Patent expiration dates:
- May 3, 2033✓✓
- May 3, 2033
-
Compositions and methods for ophthalmic and/or other applications
Patent 10,646,437
Issued: May 12, 2020
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Chen Hongming & Bourassa James
Assignee(s): The Johns Hopkins UniversityParticles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Compositions and methods for ophthalmic and/or other applications
Patent 10,688,045
Issued: June 23, 2020
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Chen Hongming & Bourassa James
Assignee(s): The Johns Hopkins UniversityParticles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Compositions and methods for ophthalmic and/or other applications
Patent 10,864,219
Issued: December 15, 2020
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Chen Hongming & Bourassa James
Assignee(s): The Johns Hopkins UniversityParticles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Compositions and methods for ophthalmic and/or other applications
Patent 11,219,597
Issued: January 11, 2022
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Chen Hongming & Bourassa James
Assignee(s): The Johns Hopkins UniversityParticles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033✓
- May 3, 2033
-
Patent 11,642,317
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Patent 11,872,318
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent 9,056,057
Issued: June 16, 2015
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Bourassa James & Gardner Colin R. & Chen Hongming & Ensign Laura M. & Lai Samuel K. & Yu Tao & Hanes Justin & Yang MingNanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Patent expiration dates:
- May 3, 2033✓✓
- May 3, 2033
-
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent 9,393,213
Issued: July 19, 2016
Inventor(s): Popov Alexey & Enlow Elizabeth & Bourassa James & Gardner Colin R & Chen Hongming & Ensign Laura M & Lai Samuel K & Yu Tao & Hanes Justin & Yang Ming
Assignee(s): Kala Pharmaceuticals, Inc.Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent 9,532,955
Issued: January 3, 2017
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Bourassa James & Gardner Colin R. & Chen Hongming & Ensign Laura M. & Lai Samuel K. & Yu Tao & Hanes Justin & Yang MingNanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent 9,737,491
Issued: August 22, 2017
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Bourassa James & Gardner Colin R. & Chen Hongming & Ensign Laura M. & Lai Samuel K. & Yu Tao & Hanes Justin & Yang Ming
Assignee(s): The Johns Hopkins UniversityNanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Patent expiration dates:
- May 3, 2033✓
- May 3, 2033
-
Compositions and methods for ophthalmic and/or other applications
Patent 9,827,191
Issued: November 28, 2017
Inventor(s): Popov Alexey & Enlow Elizabeth M. & Chen Hongming & Bourassa James
Assignee(s): The Johns Hopkins UniversityParticles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Patent expiration dates:
- May 3, 2033✓✓
- May 3, 2033
More about Inveltys (loteprednol ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic steroids
- Breastfeeding
- En español
Patient resources
Other brands
Lotemax, Alrex, Eysuvis, Lotemax SM
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.